Stay updated with breaking news from Aurase Wound. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Funding will support the development of Aurase Wound Gel and progress toward further Phase II clinical trials of innovative wound debriding enzyme SOLASCURE Ltd (SolasCure), a biotechnology company
SOLASCURE Ltd (SolasCure), a biotechnology company developing a hydrogel containing a recombinant enzyme derived from maggots which aims to accelerate wound debridement, has announced the completion of its GBP 10.9m (c. USD 13.3m) Series B investment round. The funding round was led by Seneca Partners and also included industry veterans, institutional venture and strategic investors, including BRAIN Biotech AG, EVA Pharma, Jonathan Milner, and Wealth Club.
Company is developing a therapy containing an enzyme cloned from medical maggots - News - PharmaTimes